Non- complicated uroinfections - what is new and what has changed
Authors:
MUDr. Ivan Kolombo; Febu
Authors‘ workplace:
Urologická ambulance Městské nemocnice Turnov
Published in:
Urol List 2005; 3(2): 13-29
Overview
Urinary tract infections (UTI), together with respiratory infects, belong to the most frequent inflammatory diseases at all and they occur at both sexes during the lifetime. Considering the anatomic proportions and common communication of lower urinary tract and sexual organs in men, the inflammatory diseases of male sexual organs are also ranked to this issue. UTI are frequent cause of morbidity and in complicated cases they may also lead to a significant mortality [97]. Better understanding of pathogenesis and the role of host and bacterial factors participating in the development of UTI makes possible to identify the risk patients, to minimize the consequences of the disease or enforced treatment and that way to improve the fate of the affected people. Rational pharmacotherapy, including the use of modern antimicrobial drugs, enables to reduce the morbidity and connected costs which are not small. This comprehensive article deals with non-complicated uroinfections. The problem of complicated UTI and sexually transmitted diseases (STD) will be mentioned only in basic level, unavoidable for explanation of neccessary relationships related to non-complicated UTI and it will be discussed in detail in separate articles.
KEY WORDS:
urinary infections, diagnostics, therapy, prophylaxis
Sources
1. Avorn J, Monane M, Gurwitz JH. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA 1994; 271: 751-754.
2. Bager F, Aarestrup FM, Madsem M, Wegener HC. Glycopeptide resistance in Enterococcus faecium from broilers and pigs following discontinued use of avoparcin. Microb Drug Resist 1999; 5: 53-56.
3. Bailey RR. Management of lower urinary tract infections. Drugs 1993; 45(Suppl 3): 134-139.
4. Bartoníčková K. Infekce dolních močových cest. Doporučené postupy pro praktické lékaře. Projekt MZ ČR zpracovaný ČLS JEP 2001; (http://www.cls.cz/dp).
5. Bartoníčková K. Infekce močových cest u urologických nemocných. In: Teplan V et al. Infekce ledvin a močových cest v dospělém a dětském věku. Praha: Grada Publishing 2004: 127-151.
6. Bartoníčková K. Nespecifické močové infekce. In: Dvořáček J et al. Urologie. Praha: ISV nakladatelství 1998: 683-738.
7. Bartoníčková K. Uroinfekce. Praha: Galén 2000.
8. Bauer SB, Kord SA, Jayanthi VR. Voiding dysfunction in children: neurogenic and non-neurogenic. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ. Campbell´s Urology CD-Rom. Vol 3, Section 9, Chapter 64, Copyright 2003, Elsevier Science (USA).
9. Bebear CM, Renaudin H, Schaeverbeke T et al. In-vitro activity of grepafloxacin, a new floroquinolone, against mycoplasmas. J Antimicrob Chemother 1999; 43: 711.
10. Bébrová E. Mikrobiologické aspekty patogeneze infekcí močových cest. In: Teplan V et al. Infekce ledvin a močových cest v dospělém a dětském věku. Praha: Grada Publishing 2004: 31-43.
11. Bichler KH. Urovaxom-a metaanalysis. Presented at 7th International Symposium on Clinical Evaluation of Drug Efficacy in UTI. International Society of Chemotherapy Commission for Urinary Tract Infection. Amsterdam, The Netherlands, July 1-3, 2001.
12. Bishop MC. Uncomplicated urinary tract infection. EAU Update Series 2004; 2: 143-150.
13. Bishop MC. Update on urinary tract infection. EAU Update Series 2004; 2: 93.
14. Bjerklund Johansen TE. Bacteriuria and Prophylaxis. EAU Update Series 2004; 2: 136-142.
15. Bjerrum L, Dessau RB, Hallas J. Treatment failures after antibiotic therapy of uncomplicated urinary tract infections: A prescription database study. Scand J Prim Health Care 2002; 20: 97-101.
16. Broïák M. Dysfunkce dolních močových cest. Medicína v praxi 2001; 5-6: 56-58.
17. Canag G, Levy O, Furuta GT et al. Rapid mediator induced expression of bactericidal permeability increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci 2002; 99: 3902-3907.
18. Cattell WR. Urinary tract infection: definitions and classifications. In: Cattell WR. Infections of the kidney and urinary tract. Oxford: Oxford University Press 1996: 1-7.
19. Constantinides C, Manousakas T, Nikolopoulos P, Stanitsas A, Haritopoulos K, Giannopoulos A. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int 2004; 93(9): 1262-1266.
20. Cooper J, Raeburn AL, Brumfitt W, Hamilton-Miller JM. General practitioner study: fosfomycin trometamol versus amoxycillin clavulanate in acute urinary tract infections. Chemotherapy 1990; 36(Suppl 1): 24-26.
21. Doyle SE, O´Connell RM, Miranda GA et al. Toll-like receptors induce a phagocytic gene program through p38. J Exp Med 2004; 199: 81-90.
22. Duffy LM, Cleary J, Ahern S. Clean and sterile intermittent catheterization: safe, cost-effective bladder management for male residents of VA nursing homes. J Am Geriatr Soc 1995; 43: 865-870.
23. Dvořáček J. Vyšetřovací metody moče a uretrálních sekretů. In: Dvořáček J et al. Urologie. Praha: ISV 1998; 1. vol: 125-137.
24. File TM. Overview of resistance in the 1990s. Chest 1999; 115(Suppl 3): 3-8.
25. Fleet JC. New support for a folk remedy: cranberry juice reduces bacteriuria and pyuria in elderly women. Nutr Rev 1994; 52: 168.
26. Foxman B, Frerichs RR. Epidemiology of UTI: I. Diaphragm use and sexual intercourse. Am J Public Health 1985; 75: 1308-1313.
27. Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity and economic costs. Am J Med 2002; 113 (Suppl 1A): 5-13.
28. Frendeus B, Godaly G, Hang L, Karpman D, Svanborg C. Interleukin-8 receptor deficiency confers susceptibility to acute pyelonephritis. J Infect Dis 2001; 183(Suppl 1): S 56-60.
29. Ganz T. Defensins. Antimicrobial peptide sof innate imunity. Nature Rev Immunol 2003; 3: 710-720.
30. Godaly G, Bergsten G, Hang L, Fischer H, Frendeus B, Lundstedt AC. Neutrophil recruitment, chemokine receptors, and resistence to mucosal infection. J Leukoc Biol 2001; 69(6): 899-906.
31. Hannan PC, Woodnutt G. In vitro activity of gemifloxacin (SB265805;LB20304a) against human mycoplasmas. J Antimicrob Chemother 2000; 45: 367.
32. Hanuš T, Zámečník L. Diagnostika. In: Intersticiální cystitida. Hradec Králové: NUCLEUS HK 2002: 13-33.
33. Hanuš T. Tuberculosis of the urinary tract. In: Course book of 2nd European Urological Winter Escape Meeting, Tenerife, Spain 2003. Arnhem: ESU Office 2003; 78-92.
34. Harding GK, Ronald AR, Nicolle LE, Thomson MJ, Gray GJ. Long-term antimicrobial prophylaxis for reccurent urinary tract infection in women. Rev Infect Dis 1982; 4: 438-443.
35. Henig YS, Leahy MM. Cranberry juice and urinary-tract health: science supports folklore. Nutrition 2000; 16: 684.
36. Hooton TM, Scholes D, Hughes JP. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 1996; 335: 468-474.
37. Hooton TM. Recurrent urinary tract infection in women. Int J Antimicrob Agents 2001; 17: 259-268.
38. Horáčková M . Infekce močového traktu - vyšetřovací metody. In: Teplan V, Horáčková M, Bébrová E, Janda J et al. Infekce ledvin a močových cest v dospělém a dětském věku. Praha: Grada Publishing 2004: 17-30.
39. Horčička L, Kolařík D. Záněty dolních močových cest. In: Halaška M et al. Urogynekologie. Praha: Galén 2004; 63-69.
40. Hull R, Rudy D, Donova D, Svanborg C, Wiesner I, Stewart C et al. Urinary tract infection prophylaxis using Escherichia coli 83972 in spinal cord injured patients. J Urol 2000; 163: 872.
41. Chmel R. Močová inkontinence a uroinfekce u žen v postmenopauze. Lek Listy 2003; 38: 19-22.
42. Jakobsson B, Esbjorner E, Hansson S. Minimum incidence and diagnostic rate of first urinary tract infection. Pediatrics 1999; 104: 222-226.
43. Janda J. Infekce močových cest u dětí. In: Teplan V, Horáčková M, Bébrová E, Janda J et al. Infekce ledvin a močových cest v dospělém a dětském věku. Praha: Grada Publishing 2004: 93-114.
44. Jantausch PA, Rifai N, Getson P, Akrem S, Majd M, Wiedermann BL. Urinary N-acetyl-beta-glukosaminidase and beta-2-microglubulin in the diagnosis of urinary tract infections in fibrile infants. Pediatr Infect Dis J 1994; 13(4): 294-299.
45. Jarvis WR. Selected aspectsof the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol 1996; 17: 552-557.
46. Jepson RG, Mihaljevic, L, Craig J. Cranberries for the prevention of urinary tract infections (Cochrane Review). In: Cochrane Library, Issue 4. Oxford: Update Software 1998.
47. Karram MM. Lower urinary tract infection. In: Ostergard DR, Bent AE (eds). Urogynecology and urodynamics: theory and practice. 3rd ed. Baltimore: Williams & Wilkins 1991; 306-328.
48. Kass EH. Asymptomatic infections of the urinary tract. Trans Assoc Am Physcians 1956; 69: 56.
49. Kasten MJ, Olson D, Marroquin R, Grubbs N, Strike D, Robinson S, Greer N, Meyer J. Health Care Guideline: Uncomplicated Urinary Tract Infection in Women. 9th ed. Bloomington: Institute for Clinical Systems Improvement Health Care Guideline (www.icsi.org) 2004: 1-21.
50. Kaufman JE, Anderson K, Parsons CL. Inactivation of antiadherence effect of bladder surfaře glycosaminoglycans as possible mechanism for carcinogenesis. Urology 1987; 30: 255-288.
51. Kawaciuk I. Nespecifické infekce v urogenitálním systému In: Kawaciuk I. Urologie obecná a speciální. Jinočany: H&H vydavatelství 1992: 78-99.
52. Kladenský J, Pacík D, Čermák A. Nifuratel tbl. v léčbě akutní nekomplikované uroinfekce. Česká urologie 1998; 5: 8-10.
53. Kladenský J, Pacík D. Infekce močových cest u dopělých. Aspekty komplikací nesprávné či pozdní diagnózy a neadekvátní léčby. Forum Medicinae 2001; 4: 21-26.
54. Klečka J, Hora M, Boudová L, Michal M. Cystitis cystica - příčiny, diagnostika, léčba: kasuistika. Česká urologie 2003; 2: 33-36.
55. Kolář M, Čekanová L, Urbánek K, Koukalová D. Antibiotická léčba komunitních infekcí dolních močových cest. Urolog pro praxi 2002; 3: 242-245.
56. Kolombo I, Berndt D, Pabišta R, Smetana L, Porš J et al. Problémy současných STD v naší urologické praxi. Urologie pro praxi 2004; 5: 29-30.
57. Kolombo I, Berndt D, Pabišta R, Smetana L, Porš J et al. TBC v ordinaci urologa - stále aktuální téma.Urologie pro praxi 2003; 4: 251-253.
58. Kontiokari T, Sundquist K, Nuutinen M, Pokka T, Koskela M, Uhari M. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 2001; 322: 1571.
59. Krčméry S. Predhovor. In: Teplan V et al. Infekce ledvin a močových cest v dospělém a dětském věku. Praha: Grada Publishing 2004: 13-14.
60. Krieger JN. Urinary tract infections: What´s new? J Urol 2002; 168: 2351-2358.
61. Kucheria R, Sheerin NS, Dasgupta P, Khan MS. Urinary tract ifections: advenced and new therapies. BJU Int 2004; 93(6): 690-691.
62. Kunin CM. Guidelines for the evaluation of new anti-infective drugs for the treatment of UTI: additional consideration. Clin Inf Dis 1992; 15: 1041-1044.
63. Langermann S, Mollby R, Burlein JE et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic E. coli. J Infect Dis 2000; 181: 774-778.
64. Leibovici L, Wysenebek AJ. Single dose antibiotik treatment for symptomatic urinary tract infections in women: an analysis of randomised trials. Q J Med 1991; 285: 43-57.
65. Louda M, Žák P, Pacovský J, Salavec M, Loudová M, Zachoval R, Ságlová S. Toxická epidermální nekrolýza u pacienta léčeného trimethoprim/sulfamethoxasolem. Česká urologie 2001; 5: 12-14.
66. Manges AR. Molecular epidemiology of acute, uncomplicated urinary tract infections in young women. Curr Infect Disease Rep 2003; 5: 504-509.
67. Matoušková M, Rollová M. Imunomodulace probiotiky v léčbě recidivujících zánětů dolních močových cest. Česká urologie 2001; 4: 39 (abstrakt 52).
68. Matoušková M, Rollová M. Význam imunostimulační léčby u recidivujících zánětů dolních močových cest. Česká urologie 2000; 3: 34 (abstrakt 51).
69. Mečl J. Naše přístupy pro antibakteriální profylaxi urologických výkonů. Česká urologie 2000; 3: 34 (abstrakt 50).
70. Members of the ECLM and ESCMID Working Party, Articles European Urinalysis Guidelines: Summary Scandinavian Journal of Clinical and Laboratory Investigation. Vol. 60, No.4, Suppl. 231, August 2000.
71. Merta M. Infekce horních cest močových - akutní pyelonefritida. Lék Listy 2002; 22: 14-16.
72. Morales A, Emerson L, Nickel JC. Intravesical hyaluronic acid in the treatment of refraktory interstitial cystitis. Urology 1997; 49(Suppl 5A): 111-113.
73. Mulvey MA, Joel SD, Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infection Immunity 2001; 69: 4572-4579.
74. Naber KG, Bergman B, Bishop MC, Bjerklund Johansen TE, Botto H, Lobel B, Jimenez Cruz F, Selvaggi FP. Guidelines of Urinary and Male Genitál Tract Infections. European Association of Urology (Update March 2004) (http://www.uroweb.org/).
75. Naber KG. Complicated urinary tract infections - part two. In: Naber KG. Lectures in hospital infections. London: Science Press Ltd 2003: 1-13.
76. Nickel JC. Akutní pyelonefritida u dospělých. AUA Update Series 2003, české vydání. Praha: MMN - Mezinárodní medicínské nakladatelství 2003.
77. Nicolle LE, Harding GK, Thomson M, Kennedy J, Urias B, Ronald AR. Efficacy of five years of continuous, low-dose trimethoprim-sulfamethoxazole prophylaxis for urinary tract infection. J Infect Dis 1988; 157: 1239-1242.
78. Nicolle LE, Ronald AR. Recurrent UTI in adult women: diagnosis and treatment. Inf Dis Clin North Am 1987; 1: 793-806.
79. Nicolle LE. Urinary tract infection in long-term-care facilities. Clin Infect Dis 2000; 31: 757.
80. Nicolle LE. Urinary tract infection: traditional pharmacologic therapies. Am J Med 2002; 113(Suppl 1A): 35S-44S.
81. Norrby SR. Short term treatment of uncomplicated lower urinary tract infections in woman. Rev Infect Dis 1990; 12: 458-467.
82. Okada H, Shigemura K, Tanaka K, Hinata N, Shirakawa T, Gotoh A, Hamaguchi Y, Arakawa S, Kamidono S. A new rapid bacterial drug susceptibility testing method in the urinary tract infection using flow-cytometry. Jour Urol 2003; 169(Suppl 4): 7.
83. Parsons CL. Bladder surface glycosaminoglycans - efficient mechanism of environmental adaption. Urology 1986; 27(Suppl 2): 9-14.
84. Parsons CL. Epithelial coating techniques in the treatment of interstitial cystitis. Urology 1997; 49(Suppl 5A): 100-104.
85. Quatan N, Kirby RS. Improving outcomes in Fournier´s gangrene. BJU Int 2004; 93(9): 691-692.
86. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with reccurent urinary tract infections. N Engl J Med 1993; 329: 753-756.
87. Reid G, Bruce AW, Tailor M. Instillation of lactobacillus and stimulation of indigenous organism to prevent recurrent UTI. Micro Exil Ther 1995; 23: 32-45.
88. Reid G. Potential preventative strategies and therapies in UTI. World J Urol 1999; 17: 359-363.
89. Ribeiro RM, Rossi P, Pacetta AM, Haddad JM, Pinotti JA. Therapy of uncomplicated urinary tract infections. Int Urogynecol J 2002; 13: 190-194.
90. Roberts JA, Kaack MB, Langermann S. FIMCH vaccine against a pyelonephritic E. coli. J Urol 2001; 165(Suppl): 27.
91. Rubin RH, Shapiro ED, Andriol VT, Davies RJ, Stamm WE, with modifications by a European Working Party. General guidelines for the evaluation of new anti-infective drugs for the treatment of UTI. Taufkirchen, Germany. The European Society of Clinical Microbiology and Infectious Diseases 1993; 294-310.
92. Rubin RH, Shapiro ED, Andriol VT, Davies RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of UTI. Clin Infect Dis 1992; 15(Suppl 1): S216-S227.
93. Rutledge KA,MacDonald HP. Costs of treating simple nosocomial urinary tract infection. Urology 1985; 26(Suppl 1): 24-26.
94. Sabra R. Uroinfekce v dospělém věku. In: Sabra R et al. Infekce v urologii. Praha: StudioGea 1995; 44-66.
95. Sanford JP. Urinary tract symptomas and infections. Ann Rev Med 1975; 26: 485-496.
96. Schaeffer AJ, Stuppy BA. Efficacy and safety of selfstart therapy in women with reccurent urinary tract infections. J Urol 1999; 161: 207.
97. Schaeffer AJ. Infections of the urinary tract. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ. Campbell´s Urology CD-Rom, Vol 1, Section 4, Chapter 14, Copyright 2002, Elsevier Science (USA).
98. SchiOtz HA, Guttu K. Value of urinary prophylaxis with methenamine in gynecologic surgery. Acta Obstet Gynecol Scand 2002; 81: 743-746.
99. Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gusta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. J Infect Dis 2000; 182: 1177.
100. Springall T, Sheerin NS, Abe K, Bolera VM, Wan H, Sacks SH. Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli. Nature Med 2001; 7: 803-808.
101. Stamm WE. An epidemic of urinary tract infection? New Engl J Med 2001; 14: 1055-1056.
102. Svanborg C, Bergsten G, Fischer H, Frendeus B, Godaly G, Gustafsson E. The "innate" host response protects and damages the infected urinary tract. Ann Med 2001; 33(9): 563-570.
103. Takashi D, Schin-ichi M. Mycoplasma genitalium: Another important pathogen of nongonococcal uretritis. J Urol 2002; 167: 1210-1217.
104. Tammen H. The German urinary tract infection study group. Immunobiotherapy with urovaxom in recurrent urinary tract infection. Br J Urol 1990; 65: 6-9.
105. Tenke P, Jackel M, Nagy E. Prevention and treatment of catheter-associated infections: Myt hor reality? EAU Update Series 2004; 2: 106-115.
106. Vrána J. Infekce močových cest u dětí. Urologie pro praxi 2004; 1: 10-13.
107. Wagenlehner FME, Naber KG. Antibiotics and resistence of uropathogens. EAU Update Series 2004; 2: 125-135.
108. Watson AR. Pediatric urinary tract infection. EAU Update Series 2004; 2: 94-100.
109. Weiser AC, Schaeffer AJ. Antimikrobní léčiva v urologii: správná a nesprávná preskripce. AUA Update Series 2002, české vydání. Praha: MMN - Mezinárodní medicínské nakladatelství 2002.
110. World Health Organization Report on the Tuberculosis Epidemic, 1997. Geneva, Switzerland, WHO 1997.
111. Wullt B, Bergsten G, Connell H, Rolland P, Gebretsadik N, Hull R. P fimbriae enhance the early establishment of Escherichia coli in the human urinary tract. Mol Microbiol 2000; 38(3): 456-64.
112. Wullt B, Bergsten G, Fischer H. Application of laboratory research in UTI. EAU Update Series 2004; 2: 116-124.
113. Zachoval R, Záleský M, Heráček J, Lukeš M, Kuncová J, Urban M. Neurogenní dysfunkce dolních močových cest. Urol pro praxi 2004; 2: 73-77.
114. Zámečník L. Močové infekce - nespecifické infekce horních močových cest. Postgraduální medicína 2003; 8: 824-827.
115. Zvara V. Symptomatológia urologických chorôb. In: Zvara V et al. Klinická urológia. Martin: Vydavatelstvo Osveta 1990: 53-61.
Labels
Paediatric urologist UrologyArticle was published in
Urological Journal
2005 Issue 2
Most read in this issue
- Mycotic infections
- URINARY TRACT INFECTIONS IN CHILDREN AND DURING PREGNANCY
- Septic shock at uroinfections
- The principles of antimicrobial treatment in uroinfections